Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Loren S. Michel et al.|Clinical Cancer Research|2020Cited by 368
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersLiye Zhou, Ravindra Uppaluri, Zexian Zeng et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 51
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell CarcinomasTenny Mudianto, Ravindra Uppaluri, Katie M. Campbell et al.|Clinical Cancer Research|2021Cited by 40
Oral Cavity Squamous Cell Carcinoma Xenografts Retain Complex Genotypes and Intertumor Molecular HeterogeneityKatie M. Campbell, Obi L. Griffith, Tianxiang Lin et al.|Cell Reports|2018Cited by 35
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Katie M. Campbell et al.|Clinical Cancer Research|2021Cited by 14